Experienced in Febrile Neutropenia

Dr. Jose F. Leis

Hematology Oncology | Transplant Surgery
Mayo Clinic Arizona
5701 E Mayo Blvd, 
Phoenix, AZ 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
41 Years of Experience
Experienced in Febrile Neutropenia
Mayo Clinic Arizona
5701 E Mayo Blvd, 
Phoenix, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jose Leis is a Transplant Surgeon in Phoenix, Arizona. Dr. Leis has been practicing medicine for over 41 years and is rated as an Experienced provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Small Lymphocytic Lymphoma (SLL), Classical Hodgkin Lymphoma, Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 105 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Transplant Surgery
Licenses
Internal Medicine in OR
Hospital Affiliations
Mayo Clinic Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

MAYO CLINIC ARIZONA
5701 E Mayo Blvd, Phoenix, AZ 85054
Other Locations
MAYO CLINIC ARIZONA
5779 E Mayo Blvd, Speciality Building, Phoenix, AZ 85054
MAYO CLINIC ARIZONA
13400 E Shea Blvd, Scottsdale, AZ 85259

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy
Enrollment Status: Recruiting
Publish Date: October 28, 2025
Intervention Type: Genetic
Study Phase: Phase 3
Randomized Phase 2 Study Comparing Acalabrutinib to Acalabrutinib and Obinutuzumab in the Treatment of Patients With Early-Stage Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Are at High Risk of Disease Progression
Randomized Phase 2 Study Comparing Acalabrutinib to Acalabrutinib and Obinutuzumab in the Treatment of Patients With Early-Stage Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Are at High Risk of Disease Progression
Enrollment Status: Recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Acalabrutinib, Obinutuzumab
Study Phase: Phase 2
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Venetoclax, Rituximab
Study Phase: Phase 3
A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma (NHL)
A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: January 03, 2024
Intervention Type: Drug, Other, Biological
Study Drugs: Ibrutinib, Idelalisib, Pembrolizumab
Study Phase: Phase 2
A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)
A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Drug, Combination product
Study Phase: Phase 1/Phase 2
Impact of Short Term Lenalidomide on Immune Response to Prevnar 13® in Individuals With Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), and Monoclonal B Cell Lymphocytosis (MBL)
Impact of Short Term Lenalidomide on Immune Response to Prevnar 13® in Individuals With Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), and Monoclonal B Cell Lymphocytosis (MBL)
Enrollment Status: Terminated
Publish Date: January 19, 2021
Intervention Type: Biological, Other, Drug
Study Phase: Phase 2
Phase II Trial of Pentostatin, Cyclophosphamide, and Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)
Phase II Trial of Pentostatin, Cyclophosphamide, and Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Biological, Drug, Other
Study Phase: Phase 2
View 5 Less Clinical Trials

105 Total Publications

The role of imaging studies in predicting time to first treatment and overall survival in high-count monoclonal B-cell lymphocytosis.
The role of imaging studies in predicting time to first treatment and overall survival in high-count monoclonal B-cell lymphocytosis.
Journal: British journal of haematology
Published: April 12, 2025
Similar Doctors
Advanced in Febrile Neutropenia
Dr. Adrienne D. Briggs
Hematology Oncology | Hematology | Oncology
Advanced in Febrile Neutropenia
Dr. Adrienne D. Briggs
Hematology Oncology | Hematology | Oncology

Honorhealth

10460 N 92nd St, Suite 300, 
Scottsdale, AZ 
 (6.8 miles away)
480-323-1587
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Adrienne Briggs is a Hematologist Oncology specialist and a Hematologist in Scottsdale, Arizona. Dr. Briggs is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Briggs is currently accepting new patients.

Advanced in Febrile Neutropenia
Dr. Joan M. Dahmer
Hematology Oncology | Hematology
Advanced in Febrile Neutropenia
Dr. Joan M. Dahmer
Hematology Oncology | Hematology

Honorhealth Ambulatory

10510 N 92nd St, 
Scottsdale, AZ 
 (6.8 miles away)
Languages Spoken:
English, French, German, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Joan Dahmer is a Hematologist Oncology specialist and a Hematologist in Scottsdale, Arizona. Dr. Dahmer is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Lung Cancer, and Pleuropulmonary Blastoma. Dr. Dahmer is currently accepting new patients.

Advanced in Febrile Neutropenia
Dr. Leslie E. Klein
Hematology Oncology | Hematology | Oncology
Advanced in Febrile Neutropenia
Dr. Leslie E. Klein
Hematology Oncology | Hematology | Oncology

Ironwood Physicians PC

8880 E Desert Cove Ave, 
Scottsdale, AZ 
 (6.3 miles away)
480-314-6670
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Leslie Klein is a Hematologist Oncology specialist and a Hematologist in Scottsdale, Arizona. Dr. Klein is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Severe Congenital Neutropenia, Chronic Familial Neutropenia, Agranulocytosis, and Childhood Iron Deficiency Anemia. Dr. Klein is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Leis's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile